Literature DB >> 11124980

Potentiated opioid analgesia in norepinephrine transporter knock-out mice.

L M Bohn1, F Xu, R R Gainetdinov, M G Caron.   

Abstract

Several studies have shown that activation of alpha(2)-adrenergic receptors (alpha(2)ARs) leads to mild analgesic effects. Tricyclic antidepressants (TCAs), such as desipramine (DMI), which block norepinephrine transporters (NETs), also produce mild antinociception. The coadministration of either alpha(2)AR agonists or TCAs with opiates produces synergistically potentiated antinociception. It has been postulated that the analgesic effects of TCAs are determined by their ability to inhibit norepinephrine reuptake via interactions with the NET. To test this idea, we studied mice lacking a functional NET in spontaneous and morphine-induced antinociceptive paradigms. Morphine (10 mg/kg, s.c. ) treatment produced greater analgesia, as assayed in the warm water tail-flick assay, in NET-knock-out (-KO) mice than in wild-type (WT) mice. As anticipated, yohimbine, an inhibitor of alpha(2)ARs, blocked this potentiation. Moreover, a warm water swim-stress paradigm, which is known to induce the release of endogenous opioids, produced greater antinociception in NET-KO than in the WT mice. Naloxone, an inhibitor of opioid receptors, blocked the development of the swim-evoked analgesia in both WT and NET-KO mice, confirming the involvement of the endogenous opioid system. In the NET-KO mice, DMI did not further enhance analgesia but was still able to produce inhibitory effects on the locomotor activity of these mutants, suggesting that the effects of this TCA are not exclusively via interactions with the NET. In summary, these results demonstrate in a genetic model that both endogenous and exogenous opiate-mediated analgesia can be enhanced by elimination of the NET, indicating that the interaction of TCAs with NET mediates these effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124980      PMCID: PMC6773039     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

Review 1.  alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995).

Authors:  J C Eisenach; M De Kock; W Klimscha
Journal:  Anesthesiology       Date:  1996-09       Impact factor: 7.892

2.  Supraspinal and spinal delta(2) opioid receptor-mediated antinociceptive synergy is mediated by spinal alpha(2) adrenoceptors.

Authors:  T S Grabow; R W Hurley; P N Banfor; D L Hammond
Journal:  Pain       Date:  1999-10       Impact factor: 6.961

3.  The effects of tricyclic and 'atypical' antidepressants on spontaneous locomotor activity in rodents.

Authors:  J C Tucker; S E File
Journal:  Neurosci Biobehav Rev       Date:  1986       Impact factor: 8.989

4.  Effect of chronic treatment with tricyclic antidepressants upon antinociception induced by intrathecal injection of morphine and monoamines.

Authors:  D E Kellstein; R T Malseed; M H Ossipov; F J Goldstein
Journal:  Neuropharmacology       Date:  1988-01       Impact factor: 5.250

5.  Interaction of tricyclic antidepressants with opiate receptors.

Authors:  A Biegon; D Samuel
Journal:  Biochem Pharmacol       Date:  1980-02       Impact factor: 5.858

6.  Changes in sensitivity to intrathecal norepinephrine and serotonin after 6-hydroxydopamine (6-OHDA), 5,6-dihydroxytryptamine (5,6-DHT) or repeated monoamine administration.

Authors:  J R Howe; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1982-02       Impact factor: 4.030

7.  Opioid and nonopioid swim stress-induced analgesia: a parametric analysis in mice.

Authors:  J S Mogil; W F Sternberg; H Balian; J C Liebeskind; B Sadowski
Journal:  Physiol Behav       Date:  1996-01

8.  Pharmacological characterization of substance P-induced nociception in mice: modulation by opioid and noradrenergic agonists at the spinal level.

Authors:  J L Hylden; G L Wilcox
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

9.  Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats.

Authors:  Y Takano; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1992-05       Impact factor: 4.030

10.  Selective antagonism of the antinociceptive effect of intrathecally applied alpha adrenergic agonists by intrathecal prazosin and intrathecal yohimbine.

Authors:  J R Howe; J Y Wang; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1983-03       Impact factor: 4.030

View more
  38 in total

1.  Substance P, opioid, and catecholamine systems in the mouse central nervous system (CNS).

Authors:  R G Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking.

Authors:  Heinrich J G Matthies; Jessica L Moore; Christine Saunders; Dawn Signor Matthies; Lynne A Lapierre; James R Goldenring; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 3.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 4.  Conditioned pain modulation: a predictor for development and treatment of neuropathic pain.

Authors:  Yelena Granovsky
Journal:  Curr Pain Headache Rep       Date:  2013-09

5.  The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.

Authors:  Luc Jasmin; Duc Tien; David Weinshenker; Richard D Palmiter; Paul G Green; Gabriella Janni; Peter T Ohara
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.

Authors:  Liting Deng; Wan-Hung Lee; Zhili Xu; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Pharmacol Res       Date:  2016-10-20       Impact factor: 7.658

Review 7.  Physiological genomics of antidepressant targets: keeping the periphery in mind.

Authors:  R D Blakely
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

8.  Inhibition of opioid release in the rat spinal cord by alpha2C adrenergic receptors.

Authors:  Wenling Chen; Bingbing Song; Juan Carlos G Marvizón
Journal:  Neuropharmacology       Date:  2008-02-10       Impact factor: 5.250

9.  Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.

Authors:  Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

10.  Subcellular localization of the antidepressant-sensitive norepinephrine transporter.

Authors:  Heinrich J G Matthies; Qiao Han; Angela Shields; Jane Wright; Jessica L Moore; Danny G Winder; Aurelio Galli; Randy D Blakely
Journal:  BMC Neurosci       Date:  2009-06-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.